Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

APO-TEMAZEPAM 30 MG

TEMAZEPAM : 30 MG · DIN 02225972 · APOTEX INC

Health Canada status: DORMANT

What is APO-TEMAZEPAM?

APO-TEMAZEPAM 30 MG contains TEMAZEPAM : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02225972, held by APOTEX INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as dormant, status dated 21-Oct-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What else is APO-TEMAZEPAM called?

The same molecule, TEMAZEPAM, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
NormisonLatinAustralia
TemazeLatinAustralia
TEMAZEPAM-WGRLatinAustralia
TemtabsLatinAustralia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02225972
Brand nameAPO-TEMAZEPAM
Generic / active ingredientTEMAZEPAM : 30 MG
ManufacturerAPOTEX INC
Strength30 MG
Dosage formCAPSULE
Route of administrationORAL
ScheduleTARGETED SUBSTANCES (CDSA IV)
ATC codeN05CD07 TEMAZEPAM
AHFS class28:24.08
BiosimilarNo
Health Canada statusDORMANT
Status date21-Oct-2021
Original market date1996-10-02 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02225972
DIN (unpadded, as printed on some documents)2225972
Brand nameAPO-TEMAZEPAM
Active ingredient / INNTEMAZEPAM : 30 MG
ATC codeN05CD07
ATC anatomical main groupN — Nervous system
ATC therapeutic subgroupN05
AHFS class28:24.08
Health Canada scheduleTARGETED SUBSTANCES (CDSA IV)
Biosimilar biologicNo
Market authorization holderAPOTEX INC

Health Canada approved product monograph (PDF)

Which pack is which?

Strength on the label30 MG
Dosage formCAPSULE
RouteORAL

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

What can be used instead?

Other Canadian products sharing ATC code N05CD07 TEMAZEPAM. 2 of 28 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
RESTORIL15 MGCAPSULEAA PHARMA INCMARKETEDDIN 00604453
RESTORIL30 MGCAPSULEAA PHARMA INCMARKETEDDIN 00604461
APO-TEMAZEPAM15 MGCAPSULEAPOTEX INCDORMANTDIN 02225964
CO TEMAZEPAM CAPSULES 15MG15 MGCAPSULECOBALT PHARMACEUTICALS COMPANYCANCELLED POST MARKETDIN 02244814
CO TEMAZEPAM CAPSULES 30MG30 MGCAPSULECOBALT PHARMACEUTICALS COMPANYCANCELLED POST MARKETDIN 02244815
DOM-TEMAZEPAM15 MGCAPSULEDOMINION PHARMACALCANCELLED POST MARKETDIN 02229756
DOM-TEMAZEPAM30 MGCAPSULEDOMINION PHARMACALCANCELLED POST MARKETDIN 02229758
GEN-TEMAZEPAM 15MG15 MGCAPSULEGENPHARM ULCCANCELLED POST MARKETDIN 02231615
GEN-TEMAZEPAM 30MG30 MGCAPSULEGENPHARM ULCCANCELLED POST MARKETDIN 02231616
NTP-TEMAZEPAM15 MGCAPSULENT PHARMA CANADA LTDCANCELLED PRE MARKETDIN 02347865

Who else supplies TEMAZEPAM worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. TEMAZEPAM appears in 103 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does TEMAZEPAM cost around the world?

TEMAZEPAM is listed on 4 national price registers Nexara tracks, across 63 pack listings published on 4 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
United Statesacquisition43703 Sep 2026
Australiaex-manufacturer52008 Sep 2026
United Kingdomhospital3331 Aug 2026
South Africasingle exit price2301 Sep 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

How can I get it?

This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.

Ask about sourcing APO-TEMAZEPAM

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02225972. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.